Skip to main content

Trials in Development

This quarter's most recent list of pending trials with general time frames to expected activation. 

The planned and recently activated trials lists below is the most up to date and is dynamically generated from our database. 

Planned trials

ALC9

Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)

CE10

VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma

CO33

Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial

HE2

STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)

More >>

MD1

CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

SC31

Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)

SR8

NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)

ME18

HN14

Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC

MA42

No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)

Recently activated

BLC6

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer

More >>

BR38

Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

More >>

HN13

Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer

More >>

ME17

LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma

More >>

PR26

Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)

More >>

SKC1

Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

More >>

SRC8

Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

More >>

Patients Stories

Sarcoma immunotherapy trial SRC8 opens accross Canada

Sarcoma immunotherapy trial SRC8 opens accross Canada

The SRC8 clinical trial is now open for enrollment and will investigate whether a combination of immunotherapy and chemotherapy is more effective than chemotherapy alone for adults with advanced sarcoma, specifically undifferentiated pleomorphic or poorly differentiated sarcoma subtypes.

More >>
 
The innovative ME17 melanoma trial has opened to enrollment

The innovative ME17 melanoma trial has opened to enrollment

One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.

More >>
 
La période d’inscription à l’essai novateur sur le mélanome ME17 est commencée.

La période d’inscription à l’essai novateur sur le mélanome ME17 est commencée.

La Dre Rahima Jamal et Camille Amiel préparent le patient à prendre les capsules de microbiote fécal. Photo : Centre hospitalier de l’Université de Montréal (CHUM)


English: The innovative ME17 melanoma trial has opened to enrollment

 

More >>
 
The BLC6 urothelial bladder cancer clinical trial is now open nationally

The BLC6 urothelial bladder cancer clinical trial is now open nationally

The new BLC6 MODERN phase II/III clinical trial will investigate the role of circulating tumour DNA (ctDNA) in the blood to see if it is an effective guide for what type of immunotherapy is most effective.

More >>